Kuchař et al., 2014 - Google Patents
Human interleukin‐23 receptor antagonists derived from an albumin‐binding domain scaffold inhibit IL‐23‐dependent ex vivo expansion of IL‐17‐producing T‐cellsKuchař et al., 2014
View PDF- Document ID
- 17760359659978271569
- Author
- Kuchař M
- Vaňková L
- Petroková H
- Černý J
- Osička R
- Pelák O
- Šípová H
- Schneider B
- Homola J
- Šebo P
- Kalina T
- Malý P
- Publication year
- Publication venue
- Proteins: Structure, Function, and Bioinformatics
External Links
Snippet
Engineered combinatorial libraries derived from small protein scaffolds represent a powerful tool for generating novel binders with high affinity, required specificity and designed inhibitory function. This work was aimed to generate a collection of recombinant binders of …
- 230000027455 binding 0 title abstract description 119
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kuchař et al. | Human interleukin‐23 receptor antagonists derived from an albumin‐binding domain scaffold inhibit IL‐23‐dependent ex vivo expansion of IL‐17‐producing T‐cells | |
| US11673932B2 (en) | Fusion molecules and IL-15 variants | |
| EP2035452B1 (en) | Soluble heterodimeric receptors and uses thereof | |
| JP2018526989A (en) | Novel fusion polypeptide specific for LAG-3 and PD-1 | |
| CN106589129A (en) | Three-function molecule combining CD19, CD3 and CD28 and application of three-function molecule | |
| CN107636014A (en) | Anticancer fused polypeptide | |
| Hecht et al. | ILDR2 is a novel B7-like protein that negatively regulates T cell responses | |
| JP2021533203A (en) | A novel fusion protein specific for CD137 and PD-L1 | |
| Křížová et al. | p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells | |
| Takheaw et al. | Interaction of CD99 and its ligand upregulates IL-6 and TNF-α upon T cell activation | |
| Boshuizen et al. | A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2) | |
| Khedri et al. | Development and evaluation of novel aptamers specific for human PD1 using hybrid systematic evolution of ligands by exponential enrichment approach | |
| Kums et al. | Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins | |
| WO2018167481A1 (en) | Method of selecting for antibodies | |
| EP2922560B1 (en) | Polypeptide antagonists of human il-23 receptor for treatment of autoimmune diseases | |
| Hosseininejad-Chafi et al. | Development of a functional nanobody targeting programmed cell death protein-1 as immune checkpoint inhibitor | |
| Poderoso et al. | Analysis of the expression of porcine CD200R1 and CD200R1L by using newly developed monoclonal antibodies | |
| Patra et al. | Preliminary Investigation and Therapeutic Efficacy Determination of a Novel Anti-IL-17A Antibody, Indikizumab | |
| JP2023116826A (en) | antigen binding molecule | |
| Lee et al. | Expression, purification and characterization of recombinant interleukin-21 | |
| CZ307849B6 (en) | Polypeptides for treating autoimmune diseases based on blocking the p19 subunit of the human IL-23 cytokine | |
| Dilly et al. | Tyrosine Sulfation Modulates the Binding Affinity of Chemokine-Targeting Nanobodies | |
| Sprong | Analysis of the Interaction Between Recombinant Human Beta2 Integrin I-domains and CD23 |